Haemophilus Influenzae Type b Clinical Trial
Official title:
Study to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC With Priorix™, Versus MenC-CRM197 Vaccine With Hiberix™ & Priorix™ in Toddlers Primed With Hib But Not MenC & to Evaluate Persistence up to 5 Years After Vaccination.
Verified date | September 2016 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the primary phase of the study is to demonstrate the non-inferiority of a
single dose of GSK Biologicals' Haemophilus influenzae type b and meningococcal C (Hib-MenC)
conjugate vaccine when given in the second year of life to subjects primed in infancy with a
Hib vaccine, but not with a meningococcal serogroup C vaccine, versus commercially available
Hib and MenC vaccines.
In the extension phase, at Years 1, 2, 3, 4 & 5, one blood sample is taken at each year to
follow the antibody persistence up to 5 years after vaccination. No additional vaccine is
administered during the extension phase. The Protocol Posting has been updated in order to
comply with the FDA Amendment Act, Sep 2007.
Status | Completed |
Enrollment | 433 |
Est. completion date | November 6, 2007 |
Est. primary completion date | November 1, 2007 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 12 Months to 18 Months |
Eligibility |
Inclusion Criteria: Primary phase: - Subjects whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol. - A male or female between, and including, 12 and 18 months of age at the time of vaccination. - Written informed consent obtained from the parent or guardian of the subject. - Free of obvious health problems as established by medical history and clinical examination before entering into the study. - Previously completed routine childhood vaccinations to the best of his/her parents'/guardians knowledge. - Having completed primary vaccination with two doses of Haemophilus influenzae type b outer membrane protein (Hib-OMP) containing vaccine OR three doses of diphtheria, tetanus, acellular pertussis and Haemophilus influenzae type b (DTPa/Hib) containing vaccine at least 6 months before the study start. Long-term persistence phase: - Having participated in the vaccination study 106445 Exclusion Criteria: For the primary vaccination phase: - Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. - Chronic administration (defined as more than 14 days) or planned administration of immuno-suppressants or other immune-modifying drugs within six months prior to vaccination. - Planned administration/administration of a vaccine not foreseen by the protocol during the period starting from 30 days before vaccination and ending 30 days after vaccination. - Administration of a meningococcal vaccine not foreseen by the study protocol during the period starting at birth and ending at first dose. - Previous administration of a booster dose of Hib vaccine. - Previous vaccination against measles, mumps, rubella. - History of H. influenzae type b, meningococcal serogroup C and/or confirmed measles, mumps or rubella diseases. - Known exposure to measles, mumps or rubella within 30 days prior to the start of the study. - Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus infection. - A family history of congenital or hereditary immunodeficiency. - History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. - Major congenital defects or serious chronic illness. - History of neurological disorders or more than one episode of febrile convulsion. - Acute disease at the time of enrolment. - Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period. Additional exclusion criteria for the long-term persistence phase: to be checked each year. - Previous administration of a booster dose of Hib, meningococcal serogroup C vaccines. - History of H. influenzae type b, meningococcal serogroup C diseases. |
Country | Name | City | State |
---|---|---|---|
Australia | GSK Investigational Site | Carlton | Victoria |
Australia | GSK Investigational Site | Garran | Australian Capital Territory |
Australia | GSK Investigational Site | Herston | Queensland |
Australia | GSK Investigational Site | North Adelaide | South Australia |
Australia | GSK Investigational Site | Perth | Western Australia |
Australia | GSK Investigational Site | Randwick | New South Wales |
Australia | GSK Investigational Site | Westmead | New South Wales |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
Australia,
Booy R et al. Immunogenicity and safety of the Hib-MenC-TT conjugate vaccine in Hib-primed toddlers: 3 year follow-up. Abstract presented at the 7th World Congress for World Society for Pediatric Infectious Diseases (WSPID). Melbourne, Australia, 16-19 November 2011.
Booy R et al. Immunogenicity and safety of the Hib-MenC-TT conjugate vaccine in Hib-primed toddlers: 4 year follow-up. Abstract presented at the Communicable Diseases Network Australia - Communicable Diseases Control Conference 2013, Canberra, Australia, 19-20 March 2013.
Booy R et al. Prolonged immunogenicity and safety of the HibMenC-TT conjugate vaccine in Hib-Primed toddlers. Abstract presented at the PHAA Communicable Disease Conference. Canberra, Australia, 4-6 April 2011.
Booy R, Richmond P, Nolan T, McVernon J, Marshall H, Nissen M, Reynolds G, Ziegler JB, Heron L, Lambert S, Caubet M, Mesaros N, Boutriau D. Immediate and longer term immunogenicity of a single dose of the combined haemophilus influenzae type B-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in primed toddlers 12 to 18 months of age. Pediatr Infect Dis J. 2011 Apr;30(4):340-2. doi: 10.1097/INF.0b013e31820013d2. — View Citation
Booy R, Richmond P, Nolan T, McVernon J, Marshall H, Nissen M, Reynolds G, Ziegler JB, Stoney T, Heron L, Lambert S, Mesaros N, Peddiraju K, Miller JM. Three-year antibody persistence and safety after a single dose of combined haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in Hib-primed toddlers. Pediatr Infect Dis J. 2013 Feb;32(2):169-74. doi: 10.1097/INF.0b013e3182787bff. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Micrograms Per Milliliter (µg/mL) | Anti-PRP antibody concentration greater than or equal to 0.15 µg/mL is indicative of short-term protection. | 1 month after vaccination | |
Primary | Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Greater Than or Equal to 1:8 Titer | rSBA-MenC titers greater than or equal to 1:8 titer are indicative of seroprotection. | 1 month after vaccination | |
Secondary | Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Above the Cut-off Values | rSBA-MenC titers cut-off values assessed were greater than or equal to (=) 1:8 (indicative of seroprotection) and = 1:128 titers. Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at a GlaxoSmithKline (GSK) laboratory up to Year 3 after vaccination, titres were expressed as the reciprocal of the dilution resulting in 50% inhibition. For SBA testing at the Public Health England (PHE), formerly known as Health Protection Agency (HPA), at Year 4, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition. |
Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination | |
Secondary | Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Above the Cut-off Values | rSBA-MenC titers cut-off values assessed were greater than or equal to (=)1:8 (indicative of seroprotection) and 1:128 titers. For SBA testing at the PHE at Year 5, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition. | 5 years after vaccination | |
Secondary | Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers | Titers are given as Geometric Mean Titers (GMTs). Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at a GlaxoSmithKline (GSK) laboratory up to Year 3 after vaccination, titres were expressed as the reciprocal of the dilution resulting in 50% inhibition. For SBA testing at the PHE at year 4 after vaccination, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition. | Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination. | |
Secondary | Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers | Titers are given as Geometric Mean Titers (GMTs). Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at the PHE at Year 5, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition. | 5 years after vaccination | |
Secondary | Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Above Cut-off Values | Anti-PRP antibody concentration cut-off values assessed include 0.15 µg/mL (indicative of short-term protection) and 1.0 µg/mL (indicative of long-term protection). | Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination | |
Secondary | Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Above Cut-off Values | Anti-PRP antibody concentration cut-off values assessed include 0.15 µg/mL (indicative of short-term protection) and 1.0 µg/mL (indicative of long-term protection). | 5 years after vaccination | |
Secondary | Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations | Concentrations are given as Geometric Mean Concentrations (GMCs). | Prior to, 1 month , 1 year, 2 years, 3 years and 4 years after vaccination | |
Secondary | Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations | Concentrations are given as Geometric Mean Concentrations (GMCs). | 5 years after vaccination | |
Secondary | Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Above the Cut-off Values | Anti-PSC antibody concentration cut-off values assessed include greater than or equal to (=) 0.30 µg/mL and = 2.0 µg/mL. | Prior to, 1 month, 1 year, 2 years and 3 years after vaccination | |
Secondary | Anti-polysaccharide C (Anti-PSC) Antibody Concentrations | Concentrations given as Geometric Mean Concentrations (GMCs). | Prior to, 1 month, 1 year, 2 years and 3 years after vaccination | |
Secondary | Number of Subjects Reporting Solicited Local and General Symptoms | Solicited local symptoms assessed include pain, redness and swelling at the injection site. Solicited general symptoms assessed include drowsiness, fever (= 38°C), irritability and loss of appetite. |
Within 4 days (Day 0 -Day 3) after vaccination | |
Secondary | Number of Subjects Reporting Unsolicited Symptoms | Unsolicited symptom: Any adverse event (AE) reported in addition to those solicited during the clinical study. Also any solicited symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event. | Within 31 days (Day 0 - Day 30) after vaccination | |
Secondary | Number of Subjects Reporting Serious Adverse Events (SAEs) | A serious adverse event (SAE) is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study subject. For the long-term persistence phase (Years 1 through 5), only those SAEs that are determined by the investigator to have a causal relationship to the vaccination will be described individually. |
Throughout the entire study period (up to year 5) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00753649 -
Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants
|
Phase 4 | |
Completed |
NCT01214889 -
Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.
|
Phase 3 | |
Completed |
NCT00534833 -
Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™
|
Phase 3 | |
Completed |
NCT00379977 -
Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age
|
Phase 3 | |
Completed |
NCT00153556 -
Study to Eliminate Hib Carriage in Rural Alaska Native Villages
|
Phase 4 | |
Completed |
NCT02853929 -
Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery
|
Phase 4 | |
Completed |
NCT02858440 -
A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia
|
Phase 3 | |
Completed |
NCT01983540 -
Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination
|
Phase 3 | |
Completed |
NCT01878435 -
Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya
|
N/A | |
Completed |
NCT00401531 -
Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants
|
Phase 3 | |
Completed |
NCT00376779 -
Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age
|
Phase 2 | |
Completed |
NCT00831311 -
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants
|
Phase 2 | |
Completed |
NCT01457547 -
Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course
|
Phase 4 | |
Completed |
NCT00254917 -
Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines
|
Phase 4 | |
Completed |
NCT01453998 -
Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)
|
Phase 2 | |
Completed |
NCT01449812 -
Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine
|
Phase 3 | |
Completed |
NCT00808392 -
Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b
|
Phase 3 | |
Completed |
NCT00307567 -
Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488
|
Phase 2 | |
Completed |
NCT00323050 -
Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects
|
Phase 3 | |
Completed |
NCT00325156 -
Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants
|
Phase 4 |